InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Core Insights - InMed Pharmaceuticals is advancing its Alzheimer's disease program, particularly focusing on the INM-901 drug candidate, with plans to initiate a Phase 1 clinical trial in 2027 [1][3][10] INM-901 Program Outlook - INM-901 is a proprietary, orally bioavailable small molecule drug candidate that targets neuroinflammation in Alzheimer's disease by acting as a CB1/CB2 signaling agonist [3][4] - The company has generated preclinical evidence showing that INM-901 reduces inflammatory biomarkers and neurodegenerative markers, indicating its potential therapeutic effects [4][9] - The program aims to clarify its focus on neuroinflammation, which is believed to be a primary driver of Alzheimer's progression, rather than a secondary effect [4][5] Development Plans for 2026 - The company plans to conduct a pre-IND meeting with the FDA in Q3 2026 to discuss the INM-901 program, which is seen as a critical milestone [3][10] - Continued development of INM-089, a candidate for dry age-related macular degeneration, is also planned, with a pre-IND meeting targeted for Q4 2026 [6][10] - The company is executing IND-enabling pharmacology and toxicology studies, with a focus on advancing drug substance and product development [9][10] Scientific and Operational Progress - Significant progress has been made in understanding the anti-neuroinflammatory effects of INM-901, with data supporting its multifactorial mechanism of action [2][5] - Preclinical studies have shown improvements in cognitive function and neuronal regeneration, reinforcing the drug's potential efficacy [9][10] - The company is also working on optimizing drug formulation and scaling up manufacturing processes to support future studies [9][10]